Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$181.85
▼ $4.07 (-2.2%)
Market data updated: 09/17 12:01 PM
Fundamentals updated: 09/17/2026
News analyzed: 09/17/2026
Market Cap
$49.53B
Day Range
$181.29 - $186.23
52-Week Range
$127.59 - $193.07
Beta
—
Next Earnings
02.11.2026
BDX is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+25.7% (1Y)
Strengths: 9/31 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Operating margin stability
Operating margin is stable or improving over time
Quality
Biggest negative driver
DCF Fair Value
Estimated fair value: $90.30 vs. price $181.85 (-50.3%)
Fair Value
What to watch next
When today echoes the past.
70/100
Similarity
15
Historical Matches
87/100
Analog Quality
-3.7%
Median 40D Outcome
69/100
Pattern Consistency
🟢 Bullish
33%
+3.0% … +6.3%
🟡 Base
7%
-1.0% … -1.0%
🔴 Bearish
60%
-8.8% … -3.8%
Typical timeframe (based on real historical rates clearing a 60% bar): 5 trading days.
📌 Bottom line: Out of 15 similar historical cases for this stock, 33% (95% CI 15%–58%) saw the stock rise within 20 trading days, with a median gain of -2.8%.
Echo #1 — Trend Acceleration
6 occurrence(s) · 0% historical success
Historical outcome rate is not a probability — it's what happened in this specific historical sample, with a 95% confidence range.
| Horizon | Positive rate (95% CI) | Median | 25th–75th pct | Baseline median |
|---|---|---|---|---|
| 5D | 27% (11%–52%) | -1.9% | -4.2% … +0.7% | +0.3% |
| 10D | 27% (11%–52%) | -2.0% | -5.3% … +1.2% | +0.4% |
| 20D | 33% (15%–58%) | -2.8% | -7.6% … +2.1% | +0.5% |
| 40D | 33% (15%–58%) | -3.7% | -7.3% … +1.8% | +0.8% |
| 60D | 13% (4%–38%) | -2.7% | -6.5% … -0.9% | +0.7% |
Sample size: 15 analogs, each at least 10 trading days apart (no double-counted overlapping events).
What happened after each historical match (20-day return)
| Date | Similarity | Regime | 20D outcome | 60D outcome |
|---|---|---|---|---|
| 2026-01-30 | 70/100 | Uptrend | +10.4% | -6.5% |
| 2019-08-13 | 70/100 | ✓ Uptrend | +3.0% | -1.0% |
| 2020-05-15 | 69/100 | Consolidation | -9.3% | -1.3% |
| 2022-02-28 | 69/100 | Uptrend | -1.2% | -2.7% |
| 2023-08-10 | 69/100 | ✓ Uptrend | -3.8% | -6.6% |
| 2023-08-31 | 68/100 | Uptrend | -7.5% | -14.5% |
| 2026-03-04 | 67/100 | ✓ Uptrend | -8.8% | -14.2% |
| 2022-02-02 | 67/100 | Consolidation | +6.3% | -1.3% |
| 2022-05-05 | 67/100 | Consolidation | -2.8% | -6.4% |
| 2021-02-03 | 66/100 | Uptrend | -7.7% | -4.6% |
| 2023-01-19 | 66/100 | ✓ Uptrend | -4.7% | +0.9% |
| 2025-12-26 | 66/100 | Uptrend | +3.6% | +2.5% |
| 2024-08-16 | 65/100 | Consolidation | -1.0% | -0.7% |
| 2022-09-13 | 65/100 | Consolidation | -13.3% | -4.0% |
| 2025-12-11 | 63/100 | Uptrend | +1.2% | +3.6% |
Every accepted match is compared to today across 6 domains (price structure, momentum, technical, volatility, volume, relative strength) using z-scored feature distances — no single indicator dominates. Matches within 10 trading days of each other count as one event, not independent evidence. Outcome rates use a Wilson confidence interval (never a raw percentage alone), the mean return is winsorized against extreme outliers, and "Analog Quality" separately captures sample size, data completeness, and regime match — distinct from raw similarity. Relative strength is measured against SPY and against XLV (this stock's sector).
Cross-stock analogs — real other companies, not this stock's own history.
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
58
Today
60
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
14d ago · $189.36
Evidence: Euphoria score crossed 55 (now 55)
What happened after
18d ago · $189.52
Evidence: Euphoria score crossed 55 (now 56)
What happened after
26d ago · $192.00
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
26d ago · $192.00
Evidence: 9 bullish / 3 bearish technical signals agreeing
What happened after
28d ago · $187.60
Evidence: +4.0pp vs. sector average today
What happened after
28d ago · $187.60
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
28d ago · $187.60
Evidence: 9 bullish / 3 bearish technical signals agreeing
What happened after
29d ago · $182.78
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
29d ago · $182.78
Evidence: 9 bullish / 3 bearish technical signals agreeing
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of August 18, 2026
Then
60
$181.56
Now
58
$181.85
What happened since
Signals detected by this date
No signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
34
Quality
58
Value
38
Momentum
73
Risk
42
Sentiment
100
Fundamental
55
Institutional
0
Stocks with a similar DNA right now
SCANNING BDX...
Recent media coverage of **Becton Dickinson (BDX)** highlights its **strong Q2 performance**, which led to an **upward revision of its 2026 sales and earnings outlook**, despite challenges like **rising manufacturing costs, tariffs, and margin pressures**. Analysts note that while **two high-profile segments (WATCHMAN and Electrophysiology) have faced setbacks**, the company’s **core business—accounting for ~75% of revenue—remains stable**, though near-term growth is modest (~6%). Additionally, BDX was recognized as a **dividend stock** and became a **founding sponsor of the Hazardous Drug Data Consortium**, a global initiative to standardize hazardous drug safety data. The company has **outperformed the medical devices sector** in recent stock performance.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Becton Dickinson. News trend score: 100. Reason: 10 of the last 20 articles are positive, versus 0 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
36
🎯 Conviction (vs. Emotion)
41
Psychology
45
Fundamentals
55
Technical
73
Valuation
38
The price rise has far outpaced the actual improvement in fundamental data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price (3M)
+28%
Market Narrative
73
Fundamental Reality
41
Narrative Gap
+32
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market’s dominant herding behavior suggests traders are aligning with peers rather than acting on independent signals. Extreme valuation (+98% DCF) and positive sentiment (100/100) coexist with negative momentum, indicating a disconnect between price action and fundamentals—consistent with overconfidence and euphoria. The key question is whether the narrative gap (75 vs. 41) will widen further, pulling more participants into the herd or triggering a re-evaluation. Low panic selling and anchoring imply no immediate liquidation pressure, but the proximity to peer performance could signal fragility if external catalysts emerge.
Updated: 09/08/2026, 03:45 PM
What could change this?
👥 What the crowd believes
"Explore this week’s dividend updates for Dividend Champions, Contenders & Challengers—see dividend changes, upcoming ex-dividend and pay dates."
"Business units representing roughly 75% of revenue are performing consistently with their historical track record."
"Becton, Dickinson and Company has notably outperformed the Medical Devices industry over the past year, and analysts are cautiously optimistic about the stock’s prospects."
"Becton Dickinson (BDX) has become a founding sponsor of a new Medicinal Hazard Data Standardization Consortium focused on hazardous drug information."
📈 13D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Edgar Lawrence Smith — 66/100
🔴 Weakest match
Benjamin Graham (Enterprising Investor) — 10/100
🗣️ Why do they disagree?
The methodologies here split sharply between bullish and bearish views on BDX, reflecting starkly different investment philosophies. Edgar Lawrence Smith and Samuel Armstrong Nelson both see strong buy signals—Smith’s long-term hold thesis and Nelson’s cycle-based optimism suggest they’d view this stock as a durable or cyclically favorable pick. In contrast, the majority of investors, especially Benjamin Graham and his Enterprising Investor variant, dismiss it outright, with Graham’s strict defensive criteria and the Enterprising Investor’s valuation hurdles leaving little room for optimism. Meanwhile, the middle ground—represented by Malkiel/Bogle’s skepticism, Livermore’s indecision, or even Marks’ caution—highlights how this stock’s volatility and perceived risk (like Bagehot’s liquidity concerns or Veblen’s speculative growth warnings) create friction for disciplined, risk-averse investors. The divide underscores whether one prioritizes long-term fundamentals (Smith), cyclical timing (Nelson), or strict valuation discipline (Graham).
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 66
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 60
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 52
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 52
Mid-cycle — no strong signal either way
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 49
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 47
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 46
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 43
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 35
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 34
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 33
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 32
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 29
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🔴 24
Liquidity position Bagehot would flag as a real risk
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 18
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 10
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Based on the last 300 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (7 bullish · 2 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
45.4%
Operating Margin
11.8%
Net Margin
7.7%
EBITDA Margin
23.1%
ROE
6.6%
ROA
3.0%
ROIC
—
EPS
$5.83
Cash
$641.00M
Total Debt
$19.18B
Current Ratio
1.11
Debt/Equity
0.76
Total dividend per share paid each year, over the last 5 years.
| Ex-Dividend Date | Amount per Share |
|---|---|
| 9.9.2026 | $1.050 |
| 9.6.2026 | $1.050 |
| 8.6.2026 | $1.050 |
| 10.3.2026 | $1.050 |
| 9.3.2026 | $1.050 |
| 8.12.2025 | $0.825 |
| 7.12.2025 | $0.825 |
| 8.9.2025 | $0.818 |
| 7.9.2025 | $0.818 |
| 9.6.2025 | $0.818 |
| 8.6.2025 | $0.818 |
| 10.3.2025 | $0.818 |
How is Fair Value calculated? →
Current Price
$181.85
Estimated Fair Value (DCF)
$90.30
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-50.3%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
5.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 5.0% | $2.80B | $2.57B |
| 2 | 4.4% | $2.93B | $2.46B |
| 3 | 3.8% | $3.04B | $2.35B |
| 4 | 3.1% | $3.13B | $2.22B |
| 5 | 2.5% | $3.21B | $2.09B |
Base FCF (last actual year)
$2.67B
Terminal Value
$50.63B
Present Value of Terminal Value
$32.90B
Enterprise Value
$44.59B
Net Debt
$18.54B
Equity Value
$26.05B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$88.00
Tangible Book Value per Share (Tangible NAV)
-$36.78
Sentiment based on basic keywords (not AI) — 10 positive, 10 neutral, 0 negative out of the last 20 articles.
Yahoo · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 14.9.2026
PR Newswire · 14.9.2026
Trefis · 11.9.2026
Yahoo · 9.9.2026
Trefis · 9.9.2026
SeekingAlpha · 9.9.2026
GuruFocus.com · 9.9.2026
Yahoo · 9.9.2026
Yahoo · 7.9.2026
Zacks · 7.9.2026
SeekingAlpha · 4.9.2026
Yahoo · 4.9.2026
Trefis · 4.9.2026
Yahoo · 4.9.2026
Barchart · 4.9.2026
Barrons.com · 4.9.2026
Simply Wall St. · 3.9.2026
Yahoo · 3.9.2026
Becton Dickinson (BDX) currently has a StockIQ AI score of 58/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
BDX currently scores 58/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, BDX's estimated fair value is $90.30, which is 50.3% below the current price of $181.85. This is one valuation model among several signals in the fair-value category, not a price target.
BDX's technical score is 73/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Operating margin is stable or improving over time; Price is above the 50-day average; Price is above the 200-day average.
Based on the real signals StockIQ computed: Estimated fair value: $90.30 vs. price $181.85 (-50.3%); Calmar: -0.11 (3y annualized return -4.4% / max drawdown 38.2%); Earnings per share (EPS) growth: -0.7%.
Yes — BDX has a real recorded dividend payment history on StockIQ. See the Dividends section on this page for the actual per-share amounts and dates.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 8 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Roque Vitor | Tax Withholding in Shares | 2.9.2026 | 190 | -190 | — |
| Feld Michael | Open Market Sale | 26.8.2026 | 165 | -165 | $188.49 |
| Feld Michael | Open Market Sale | 26.8.2026 | 19,720 | -165 | $188.49 |
| Feld Michael | Tax Withholding in Shares | 20.8.2026 | 19,885 | -1,049 | — |
| Feld Michael | Tax Withholding in Shares | 20.8.2026 | 1,049 | -1,049 | — |
| Polen Thomas E Jr | Disposition to the Company | 13.8.2026 | 114,315 | -39,126 | $185.00 |
| Polen Thomas E Jr | Exercise of Derivative Securities | 13.8.2026 | 153,441 | +43,278 | $167.25 |
| Polen Thomas E Jr | Exercise of Derivative Securities | 13.8.2026 | 0 | -43,278 | — |
| Polen Thomas E Jr | Open Market Sale | 13.8.2026 | 110,163 | -4,152 | $185.00 |
| Polen Thomas E Jr | Open Market Sale | 13.8.2026 | 4,152 | -4,152 | $185.00 |
| Polen Thomas E Jr | Exercise of Derivative Securities | 13.8.2026 | 43,278 | -43,278 | — |
| Polen Thomas E Jr | Disposition to the Company | 13.8.2026 | 39,126 | -39,126 | $185.00 |
| Polen Thomas E Jr | Exercise of Derivative Securities | 13.8.2026 | 43,278 | +43,278 | $167.25 |
| Goette Roland | Open Market Sale | 11.8.2026 | 14,856 | -2,438 | $180.84 |
| Goette Roland | Open Market Sale | 11.8.2026 | 2,438 | -2,438 | $180.84 |
| Byington Carrie L | Grant/Award from Employer | 6.8.2026 | 94 | +94 | $165.62 |
| Huffines Robert Luther | Grant/Award from Employer | 6.8.2026 | 189 | +189 | $165.62 |
| Byington Carrie L | Grant/Award from Employer | 6.8.2026 | 3,810 | +94 | $165.62 |
| Huffines Robert Luther | Grant/Award from Employer | 6.8.2026 | 595 | +189 | $165.62 |
| Feld Michael | Open Market Sale | 27.7.2026 | 75 | -75 | $157.13 |
| Feld Michael | Open Market Sale | 27.7.2026 | 20,934 | -75 | $157.13 |
| Muhsin Bilal | Tax Withholding in Shares | 2.7.2026 | 1,935 | -1,935 | — |
| Muhsin Bilal | Tax Withholding in Shares | 2.7.2026 | 41,359 | -1,935 | — |
| Muhsin Bilal | Grant/Award from Employer | 1.7.2026 | 14,342 | +14,342 | — |
| Muhsin Bilal | Grant/Award from Employer | 1.7.2026 | 43,294 | +14,342 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
10,672,859 shares short as of 2026-08-31 · vs. 10,015,223 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
58.6% of trading volume this week was short selling, vs. 59.7% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology